The FDA approved a supplement to abbreviated new drug application ANDA040506 for ethosuximide on 11 September 2026. The applicant is Chartwell Rx.
An abbreviated application is the generic pathway, and a supplement to one is typically a manufacturing, labelling or site change rather than anything clinical. Nothing about the indication or the evidence for ethosuximide changes.
It is worth a line only because of what ethosuximide is. It remains first-line for childhood absence epilepsy on the strength of the comparison against valproate and lamotrigine, and supply of it has historically been narrow, with few manufacturers. Any addition to the supply side of a drug with a single narrow indication and no easy substitute is a small piece of good news for the families who depend on it. Availability in India is through a limited number of suppliers and is not affected by a US filing.
- Ethosuximide remains first-line for childhood absence epilepsy; nothing clinical has changed.
- A supplement to a generic application is usually a manufacturing or labelling change.
- Supply of ethosuximide is narrow, so additional approved manufacturing matters more than usual.
- No CDSCO action is implied; Indian availability is unchanged by a US filing.
- If a family reports difficulty sourcing it, check alternative suppliers before switching drug.
Why it matters
Ethosuximide has one narrow indication and few manufacturers, so supply-side news carries more weight than the approval itself.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for neurology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free